2013

Dose Escalation, Safety and Impact of Renadyl_CKD-III-IV_TJU_N&T  VIEW (PDF)


2012

Published review article entitled “Probiotics, Prebiotics and Synbiotics: Gut and Beyond” by Usha Vyas and Natarajan Ranganathan in Gastroenterology Research and Practice Volume 2012

VIEW (PDF)

Open-Label Dose Escalation Study of Kibow Biotics (Renadyl™) in Chronic Kidney Failure Stage III and IV Patients at Thomas Jefferson University began in May 2011 and completed on December 2012 . Abstract to be published in 2013 and presented at WCN-ISN 2013)

Double-blind, randomized, placebo controlled, cross-over study of Kibow Biotics in Chronic Kidney Failure Patients on Dialysis (Renadyl™) at SUNY-Downstate Medical Center began in April 2011 and completed on December 2012. Currently unblinding results, with no Renadyl™ related adverse effects reported.

VIEW

2011

Three clinical trials have been initiated:

Observational Study of Kibow Biotics (Renadyl™) in Dialysis Patients (Jefferson)

VIEW

Observational Study of Kibow Biotics (Renadyl™) in Chronic Kidney Failure Patients (Jefferson)

VIEW

Observational Study of Kibow Biotics (Renadyl™) in Chronic Kidney Failure Patients on Dialysis (SUNY-Downstate Medical Center)

VIEW

2010

Pilot Study of Probiotic Dietary Supplementation for Promoting Healthy Kidney Function in Patients with Chronic Kidney Disease

VIEW

Poster Presentation Title:"Probiotic Dietary Supplementation in Chronic Kidney Disease Patients (CKD III and IV)-Preliminary Observations and Combined Data Analysis of a 6-month Pilot Scale, Randomized, Double Blind and Crossover Study Design in Argentina, Canada, Nigeria and USA.

VIEW (PDF)

Poster Presentation Title:"Kibow’s Pathway Through a Drug Like Validation for a Probiotic Dietary Supplement Targeted for Helping Maintain a Healthy Kidney Function

VIEW (PDF)

Poster Presentation Title:"Case Study of a Patient with Juvenile Diabetes and Nephropathy using a Probiotics as a Dietary Supplement for a Continuous Three Year Period

VIEW (PDF)

 

2009

Poster Presentation Title: "Dietary Supplementation with Probiotic Formulation (Kibow Biotics®) on CKD III and IV patients – a Short Term Pilot Scale Study in Canada" presented at ASN 2009 (Oct. 27 to Nov. 1) in San Diego, CA

VIEW (PDF)

An Editorial: "Can the bowel substitute for the kidney in advanced renal failure? - Current Medical Research and Opinion, Vol.25, No.8, 2009, 1913-1918

VIEW

Brief Article: "Probiotic dietary supplementation in patients with stage 3 and 4 chronic kidney disease: a 6-month pilot scale trial in Canada." Current Medical Research and Opinion, Vol.25, No.8, 2009, 1919-1930

VIEW

Poster presentation title: Probiotics for Kidney health – Gut Based Uremic Toxin Removal – “Enteric Dialysis™” – Natarajan Ranganathan, Ph.D., and Eli A Friedman, MD at the 5th Asian Conference on Lactic Acid Bacteria Microbes in Disease Prevention, held July 1-3, 2009, Singapore.

VIEW (PDF)

Enteric Dialysis™ - Brief introduction and its potential for CKD applications - Dr. N. Ranganathan – presented as an invited speaker at symposium 7 – Renal patient, at the Parenteral & Enteric Nutrition Society of Malaysia (PENSA) held June 5 – 7, 2009, Kuala Lumpur, Malaysia.

VIEW

2008

Development of Room Temperature Stable Probiotics for CKD Applications - Presented at ASN 2008

VIEW (PDF)

Pilot Scale Human Clinical Trials with a Scientifically Validated Probiotic Formulation - Kibow Biotics® - With CKD Stage III and IV Patients (Mid-term and partial data analysis from Canada) - Presented at IDDST 2008

VIEW (PDF)

Oral ingestion of probiotics and fecal analysis in CKD III and IV patients - Preliminary observations - Presented at CPRD 2008

VIEW (PDF)

2007

Pilot Clinical Trial of Probiotic Bacteria (Kibow Biotics®) in Chronic Kidney Disease (CKD)

VIEW (PDF)

Progress in devising a bowel based probiotic therapy for uremia

VIEW (PDF)

2006

Progress in devising a bowel based probiotic therapy for uremia

VIEW (PDF)

In Vitro and In Vivo Assessment of Intraintestinal Bacteriotherapy in Chronic Kidney Disease

VIEW (PDF)

Effect of feeding Kibow Biotics® to cats and dogs in kidney failure

VIEW (PDF)

Preliminary clinical evaluation of Kibow Biotics®, a probiotic agent, on feline azotemia

VIEW (PDF)

2005

Are Clinical Trials Warranted for a Dietary Supplement with Probiotics?

VIEW

Initial Safety Studies of a Probiotic for Renal Insufficiency

VIEW

Probiotics reduces Azotemia in Gottingen Minipigs

VIEW

Probiotic Amelioration of Azotemia in 5/6th Nephrectomized Sprague-Dawley Rats

VIEW (PDF)

Short term effect of temperature on Kibow Biotics®

VIEW

Evaluation of Commercial Probiotic Products for Azotemia

VIEW

2004

An introduction to Probiotics and its potential in Clinical applications

VIEW

Comparative microbial viability analysis in two delivery formats-Gel caps or mixed with food/diet

VIEW

Gut-Based Uremia Therapy : In vitro R&D Investigations of an Oral Probiotic Microbial Formulation with the Aid of a Simulated Human Intestinal Microbial Ecosystem (SHIME) Biochemical Reactor

VIEW

Gut-Based Uremia Therapy : Oral Bacteriotherapy Effectively Reduces Severity of Azotemia in 5/6th Nephrectomized Mini Pigs

VIEW

Gut based Uremia therapy: Continued in vitro and in vivo R&D investigations on the application of oral probiotic bacteriotherapy towards Chronic Kidney Disease (CKD) patients

VIEW

Significance of dosage for effective clinical application of probiotics

VIEW

Mode of Delivery and Dosage are important factors for Uremia Therapy with Probiotics

VIEW

Probiotic Formulation in vitro effect on Phenol and p-Cresol levels

VIEW

Initial Trial of Probiotic Bacteria as Therapy for Uremia in Dogs

VIEW

Kibow Biotics is preferred and superior to yogurt for uremia applications

VIEW

Model of Chronic Renal Failure in Miniature Pigs

VIEW

Oral Probiotic treatment for Uremia in a Porcine Model of Chronic Renal Failure

VIEW

Substitution of the kidney function by the bowel in Azotemia

VIEW

2003

Artificial Swallowable Kidney Formulation

VIEW

Oral Bacteriotherapy Effectively Reduces Severity of Azotemia in 5/6th Nephrectomized Rats

VIEW

Streptococcus thermophilus KB19 is a Potential component of a Probiotic Regimen Applicable in Enteric Dialysis for Uremia

VIEW

Rate of Urea Hydrolysis by Streptococcus thermophilus KB19 is comparable to Soil Bacterium Bacillus pasteurii and Genetically Engineered Urealytic E.coli

VIEW

Probiotics Extend Survival in Untreated 5/6 Nephrectomized Rats: Possible Use for Probiotics as An Adjunct in Chronic Renal Failure (CRF)®

VIEW

2002

Probiotics to Eliminate Nitrogenous Metabolites

VIEW

A Novel Synbiotic for Augmenting Kidney Function

VIEW

Urea Hydrolysis and Ammonia Uptake by Bacillus pasteurii

VIEW

Urease Activity in Commercial Yogurt

VIEW

Bacillus pasteurii: A Small Microbe with Huge Potential

VIEW

A Nutraceutical Approach to Pre-Dialysis

VIEW

Viability of Probiotics in Gastric Juice and Artificial Intestinal Fluid

VIEW

2001

Gut Based Uremia Therapy: Simultaneously Eliminate Urea, Creatinine and Uric Acid.

VIEW